Page 56 - Haematologica Vol. 109 - July 2024

REVIEW ARTICLE - CXCL8 in primary myelofibrosis
G. Vermeersch et al.
Cell. 2019;25(3):407-418.
14. Haas S, Hansson J, Klimmeck D, et al. Inflammation-induced
emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell. 2015;17(4):422-434.
15. Johnson CB, Zhang J, Lucas D. The role of the bone marrow microenvironment in the response to infection. Front Immunol. 2020;11:585402.
16. Psaila B, Wang G, Rodriguez-Meira A, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell. 2020;78(3):477-492.
17. Melo-Cardenas J, Migliaccio AR, Crispino JD. The role of megakaryocytes in myelofibrosis. Hematol Oncol Clin North Am. 2021;35(2):191-203.
18. Larsen TE. Emperipolesis of granular leukocytes within megakaryocytes in human hemopoietic bone marrow. Am J Clin Pathol. 1970;53(4):485-489.
19. Cunin P, Nigrovic PA. Megakaryocyte emperipolesis: a new frontier in cell-in-cell interaction. Platelets. 2020;31(6):700-706.
20. Cunin P, Bouslama R, Machlus KR, et al. Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets. Elife. 2019;8:e44031.
21. Ding ZM, Babensee JE, Simon SI, et al. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol. 1999;163(9):5029-5038.
22. Spangrude GJ, Lewandowski D, Martelli F, et al. P-selectin sustains extramedullary hematopoiesis in the Gata1low model of myelofibrosis. Stem Cells. 2016;34(1):67-82.
23. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis.
Blood. 2000;96(4):1342-1347.
24. Zingariello M, Fabucci M, Bosco D, et al. Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation. Biotech Histochem. 2010;85(3):157-170.
25. Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood. 2004;104(12):3573-3580.
26. Arciprete F, Verachi P, Martelli F, et al. Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis. Exp Hematol. 2023;121:30-37.
27. Verachi P, Gobbo F, Martelli F, et al. Preclinical studies on the use of a P-selectin blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model. Exp Hematol. 2023;117:43-61.
28. Tanaka M, Aze Y, Fujita T. Adhesion molecule LFA-1/ICAM-1 influences on LPS-induced megakaryocytic emperipolesis in the rat bone marrow. Vet Pathol. 1997;34(5):463-466.
29. Perkins AC, Burbury K, Lehmann T, et al. Adore: a randomized, open-label, phase 1/2 open-platform study evaluating safety and efficacy of novel ruxolitinib combinations in patients with myelofibrosis. Blood. 2020;136(Suppl 1):52-53.
30. Campanelli R, Rosti V, Villani L, et al. Evaluation of the bioactive and total transforming growth factor b1 levels in primary myelofibrosis. Cytokine. 2011;53(1):100-106.
31. Cominal JG, Cacemiro M da C, Berzoti-Coelho MG, et al. Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Front Oncol. 2021;11:665037.
32. Chen P, Wu B, Ji L, et al. Cytokine consistency between bone marrow and peripheral blood in patients with Philadelphia- negative myeloproliferative neoplasms. Front Med. 2021;8:598182.
33. McLornan D, Szydlo R, Koster L, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25(11):2167-2171.
34. Fisher DAC, Miner CA, Engle EK, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. 2019;33(8):1978-1995.
35. Fisher DAC, Malkova O, Engle EK, et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017;31(9):1962-1974.
36. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121(24):4832-4837.
37. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002;72(5):847-855.
38. Zhao JL, Ma C, O’Connell RM, et al. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell. 2014;14(4):445-459.
39. Ketelut-Carneiro N, Fitzgerald KA. Apoptosis, pyroptosis, and necroptosis-Oh my! The many ways a cell can die. J Mol Biol. 2022;434(4):167378.
40. Longhitano L, Li Volti G, Giallongo C, et al. The role of inflammation and inflammasome in myeloproliferative disease. J Clin Med. 2020;9(8):2334.
41. Zambetti NA, Ping Z, Chen S, et al. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell. 2016;19(5):613-627.
42. Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, et al. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematol. 2018;5(9):e393-e402.
43. Rai S, Grockowiak E, Hansen N, et al. Inhibition of interleukin-1b reduces myelofibrosis and osteosclerosis in mice with JAK2- V617F driven myeloproliferative neoplasm. Nat Commun. 2022;13(1):5346.
44. Modi WS, Dean M, Seuanez HN, Mukaida N, Matsushima K, O’Brien SJ. Monocyte-derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Hum Genet. 1990;84(2):185-187.
45. Rajarathnam K, Schnoor M, Richardson RM, Rajagopal S. How do chemokines navigate neutrophils to the target site: dissecting the structural mechanisms and signaling pathways. Cell Signal. 2019;54:69-80.
46. Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593-619.
47. Bachelerie F, Ben-Baruch A, Burkhardt AM, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66(1):1-79.
Haematologica | 109 July 2024
2070